Global Fertility Testing Devices Market 2026-2035
Description
Global Fertility Testing Devices Market Size, Share & Trends Analysis by Product Type (Ovulation Prediction Kits, Fertility Monitors, and Male Fertility Testing Products), By Mode of Purchase (Over‑the‑Counter (OTC), and Prescription‑Based), By End-User (Hospitals and Fertility Clinics, and Home Care Setting), Forecast Period (2026-2035)
Industry Overview
Fertility testing devices market was valued at $2.7 billion in 2025 and is projected to reach $5.6 billion by 2035, growing at a CAGR of 7.7% during the forecast Period (2026-2035). The market growth is driven by rising delayed pregnancies, increased infertility awareness, and tech advances like AI wearables and home sperm tests, making tracking easier. Key factors boosting growth include women delaying family for careers, rising PCOS cases, easy e-commerce access, and emerging male testing, though high costs and regulatory hurdles pose challenges. North America & Europe lead, but Asia-Pacific shows high growth owing to rising awareness.
Market Dynamics
Rising Infertility Prevalence and Delayed Parenthood
Globally, infertility rates are increasing due to lifestyle changes, stress, obesity, smoking, environmental exposure, and delayed family planning. Couples are choosing to conceive later in life, which heightens the need for early and regular fertility assessment. This demographic shift has made fertility testing devices such as ovulation prediction kits, hormone-based tests, and semen analysis tools an essential first step in reproductive planning. Growing awareness about fertility health among both women and men is encouraging proactive monitoring, significantly driving demand for easy-to-use, non-invasive, and affordable testing solutions.
Technological Advancements and Shift Toward Home-Based Diagnostics
Continuous innovation in fertility testing technologies is a major growth driver. The market is witnessing a transition from conventional strip-based tests to digital fertility monitors, smartphone-connected devices, and AI-enabled hormone tracking systems. These advanced devices offer higher accuracy, real-time data interpretation, and personalized insights, improving user confidence and outcomes. The convenience, privacy, and cost-effectiveness of home-based fertility testing devices are accelerating adoption, especially among tech-savvy consumers and those seeking alternatives to frequent clinical visits.
Expansion of E-Commerce, DTC Models, And Fertility-Focused Healthcare Ecosystems
The rapid growth of e-commerce platforms and direct-to-consumer (DTC) healthcare models has significantly improved access to fertility testing devices worldwide. Online pharmacies, brand-owned websites, and subscription-based models enable discreet purchasing and repeat usage of consumables such as test strips and cartridges. Additionally, partnerships between fertility device manufacturers, telehealth providers, and fertility clinics are strengthening integrated care pathways from home testing to professional consultation thereby expanding market penetration and long-term customer engagement across developed and emerging markets.
Market Segmentation
Ovulation prediction kits (OPKs) represent the largest and leading segment in the Global Fertility Testing Devices Market, driven primarily by their widespread adoption in home care settings and strong availability through over-the-counter (OTC) channels. Within this category, urine-based ovulation kits dominate due to their high accuracy in detecting luteinizing hormone (LH) surges, affordability, ease of use, and rapid results, making them the preferred first-line fertility assessment tool for women trying to conceive. The growing awareness of reproductive health, increasing incidence of delayed pregnancies, and rising preference for non-invasive, self-administered fertility testing solutions have significantly boosted demand for OPKs compared to fertility monitors and male fertility testing products. Additionally, strong retail penetration, e-commerce growth, and minimal regulatory barriers for OTC products further reinforce the leadership of ovulation prediction kits, positioning this segment as the largest contributor to overall market revenue and growth globally.
Home Care Setting: A Key Segment in Market Growth
The home care setting represents the single most influential and fastest-growing segment in the global fertility testing devices market, driven by a strong shift toward self-managed and preventive reproductive health. Increasing awareness of fertility planning among women and couples, combined with delayed parenthood trends, has significantly boosted demand for convenient, private, and easy-to-use testing solutions that can be used at home. Home-based fertility testing devices such as ovulation prediction kits, hormone monitoring strips, and digital fertility trackers offer advantages including affordability, anonymity, and rapid results, making them highly attractive compared to clinic-based testing. The expansion of over-the-counter (OTC) availability further supports this segment, enabling consumers to purchase devices without medical consultations. Technological advancements, including smartphone connectivity, AI-based cycle tracking, and app-integrated hormone analysis, have improved accuracy and user engagement, strengthening consumer confidence in home testing.
Additionally, growing female workforce participation and busy lifestyles have increased the preference for at-home diagnostics that reduce time and cost burdens associated with hospital visits. In emerging economies, rising disposable income and expanding e-commerce platforms have improved access to home fertility testing products, accelerating adoption. Post-pandemic behavioral changes emphasizing remote and self-care diagnostics have also had a lasting positive impact. As a result, the home care setting is expected to remain the primary growth engine of the fertility testing devices market over the forecast period, outpacing hospital and clinic-based usage.
Regional Outlook
The global fertility testing devices market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global fertility testing devices market, accounting for the largest revenue share globally. This leadership is primarily driven by high awareness of fertility health, a strong culture of proactive reproductive planning, and widespread acceptance of at-home diagnostic testing. The US has a high prevalence of delayed parenthood, with many individuals choosing to conceive later in life due to career and lifestyle priorities, which significantly increases demand for ovulation prediction kits, digital fertility monitors, hormone-based tests, and at-home semen analysis devices. In addition, the country benefits from a well-established healthcare infrastructure, strong purchasing power, and extensive insurance and employer-supported fertility benefits that indirectly encourage fertility testing adoption.
The presence of leading fertility testing device manufacturers and brands such as Swiss Precision Diagnostics (Clearblue), Church & Dwight (First Response), Procter & Gamble, and several digital fertility startups further strengthens market dominance through continuous product innovation and aggressive direct-to-consumer marketing. Moreover, the rapid expansion of e-commerce, subscription-based testing models, and telehealth fertility platforms in the US has improved product accessibility and consumer engagement. Regulatory clarity for over-the-counter diagnostic devices and high penetration of digital health technologies also support faster commercialization and adoption of advanced fertility testing solutions, enabling the United States to maintain a commanding share of the global fertility testing devices market.
Market Players Outlook
The major companies operating in the global fertility testing devices market include Abbott Laboratories, Church & Dwight Co., Inc., Prestige Consumer Healthcare Inc., Swiss Precision Diagnostics (SPD) GmbH, Quidel Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
Industry Overview
Fertility testing devices market was valued at $2.7 billion in 2025 and is projected to reach $5.6 billion by 2035, growing at a CAGR of 7.7% during the forecast Period (2026-2035). The market growth is driven by rising delayed pregnancies, increased infertility awareness, and tech advances like AI wearables and home sperm tests, making tracking easier. Key factors boosting growth include women delaying family for careers, rising PCOS cases, easy e-commerce access, and emerging male testing, though high costs and regulatory hurdles pose challenges. North America & Europe lead, but Asia-Pacific shows high growth owing to rising awareness.
Market Dynamics
Rising Infertility Prevalence and Delayed Parenthood
Globally, infertility rates are increasing due to lifestyle changes, stress, obesity, smoking, environmental exposure, and delayed family planning. Couples are choosing to conceive later in life, which heightens the need for early and regular fertility assessment. This demographic shift has made fertility testing devices such as ovulation prediction kits, hormone-based tests, and semen analysis tools an essential first step in reproductive planning. Growing awareness about fertility health among both women and men is encouraging proactive monitoring, significantly driving demand for easy-to-use, non-invasive, and affordable testing solutions.
Technological Advancements and Shift Toward Home-Based Diagnostics
Continuous innovation in fertility testing technologies is a major growth driver. The market is witnessing a transition from conventional strip-based tests to digital fertility monitors, smartphone-connected devices, and AI-enabled hormone tracking systems. These advanced devices offer higher accuracy, real-time data interpretation, and personalized insights, improving user confidence and outcomes. The convenience, privacy, and cost-effectiveness of home-based fertility testing devices are accelerating adoption, especially among tech-savvy consumers and those seeking alternatives to frequent clinical visits.
Expansion of E-Commerce, DTC Models, And Fertility-Focused Healthcare Ecosystems
The rapid growth of e-commerce platforms and direct-to-consumer (DTC) healthcare models has significantly improved access to fertility testing devices worldwide. Online pharmacies, brand-owned websites, and subscription-based models enable discreet purchasing and repeat usage of consumables such as test strips and cartridges. Additionally, partnerships between fertility device manufacturers, telehealth providers, and fertility clinics are strengthening integrated care pathways from home testing to professional consultation thereby expanding market penetration and long-term customer engagement across developed and emerging markets.
Market Segmentation
Ovulation prediction kits (OPKs) represent the largest and leading segment in the Global Fertility Testing Devices Market, driven primarily by their widespread adoption in home care settings and strong availability through over-the-counter (OTC) channels. Within this category, urine-based ovulation kits dominate due to their high accuracy in detecting luteinizing hormone (LH) surges, affordability, ease of use, and rapid results, making them the preferred first-line fertility assessment tool for women trying to conceive. The growing awareness of reproductive health, increasing incidence of delayed pregnancies, and rising preference for non-invasive, self-administered fertility testing solutions have significantly boosted demand for OPKs compared to fertility monitors and male fertility testing products. Additionally, strong retail penetration, e-commerce growth, and minimal regulatory barriers for OTC products further reinforce the leadership of ovulation prediction kits, positioning this segment as the largest contributor to overall market revenue and growth globally.
Home Care Setting: A Key Segment in Market Growth
The home care setting represents the single most influential and fastest-growing segment in the global fertility testing devices market, driven by a strong shift toward self-managed and preventive reproductive health. Increasing awareness of fertility planning among women and couples, combined with delayed parenthood trends, has significantly boosted demand for convenient, private, and easy-to-use testing solutions that can be used at home. Home-based fertility testing devices such as ovulation prediction kits, hormone monitoring strips, and digital fertility trackers offer advantages including affordability, anonymity, and rapid results, making them highly attractive compared to clinic-based testing. The expansion of over the counter (OTC) availability further supports this segment, enabling consumers to purchase devices without medical consultations. Technological advancements, including smartphone connectivity, AI-based cycle tracking, and app-integrated hormone analysis, have improved accuracy and user engagement, strengthening consumer confidence in home testing.
Additionally, growing female workforce participation and busy lifestyles have increased the preference for at-home diagnostics that reduce time and cost burdens associated with hospital visits. In emerging economies, rising disposable income and expanding e-commerce platforms have improved access to home fertility testing products, accelerating adoption. Post-pandemic behavioral changes emphasizing remote and self-care diagnostics have also had a lasting positive impact. As a result, the home care setting is expected to remain the primary growth engine of the fertility testing devices market over the forecast period, outpacing hospital and clinic-based usage.
Regional Outlook
The global fertility testing devices market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global fertility testing devices market, accounting for the largest revenue share globally. This leadership is primarily driven by high awareness of fertility health, a strong culture of proactive reproductive planning, and widespread acceptance of at-home diagnostic testing. The US has a high prevalence of delayed parenthood, with many individuals choosing to conceive later in life due to career and lifestyle priorities, which significantly increases demand for ovulation prediction kits, digital fertility monitors, hormone-based tests, and at-home semen analysis devices. In addition, the country benefits from a well-established healthcare infrastructure, strong purchasing power, and extensive insurance and employer-supported fertility benefits that indirectly encourage fertility testing adoption.
The presence of leading fertility testing device manufacturers and brands such as Swiss Precision Diagnostics (Clearblue), Church & Dwight (First Response), Procter & Gamble, and several digital fertility startups further strengthens market dominance through continuous product innovation and aggressive direct-to-consumer marketing. Moreover, the rapid expansion of e-commerce, subscription-based testing models, and telehealth fertility platforms in the US has improved product accessibility and consumer engagement. Regulatory clarity for over-the-counter diagnostic devices and high penetration of digital health technologies also support faster commercialization and adoption of advanced fertility testing solutions, enabling the United States to maintain a commanding share of the global fertility testing devices market.
Market Players Outlook
The major companies operating in the global fertility testing devices market include Abbott Laboratories, Church & Dwight Co., Inc., Prestige Consumer Healthcare Inc., Swiss Precision Diagnostics (SPD) GmbH, Quidel Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
Industry Overview
Fertility testing devices market was valued at $2.7 billion in 2025 and is projected to reach $5.6 billion by 2035, growing at a CAGR of 7.7% during the forecast Period (2026-2035). The market growth is driven by rising delayed pregnancies, increased infertility awareness, and tech advances like AI wearables and home sperm tests, making tracking easier. Key factors boosting growth include women delaying family for careers, rising PCOS cases, easy e-commerce access, and emerging male testing, though high costs and regulatory hurdles pose challenges. North America & Europe lead, but Asia-Pacific shows high growth owing to rising awareness.
Market Dynamics
Rising Infertility Prevalence and Delayed Parenthood
Globally, infertility rates are increasing due to lifestyle changes, stress, obesity, smoking, environmental exposure, and delayed family planning. Couples are choosing to conceive later in life, which heightens the need for early and regular fertility assessment. This demographic shift has made fertility testing devices such as ovulation prediction kits, hormone-based tests, and semen analysis tools an essential first step in reproductive planning. Growing awareness about fertility health among both women and men is encouraging proactive monitoring, significantly driving demand for easy-to-use, non-invasive, and affordable testing solutions.
Technological Advancements and Shift Toward Home-Based Diagnostics
Continuous innovation in fertility testing technologies is a major growth driver. The market is witnessing a transition from conventional strip-based tests to digital fertility monitors, smartphone-connected devices, and AI-enabled hormone tracking systems. These advanced devices offer higher accuracy, real-time data interpretation, and personalized insights, improving user confidence and outcomes. The convenience, privacy, and cost-effectiveness of home-based fertility testing devices are accelerating adoption, especially among tech-savvy consumers and those seeking alternatives to frequent clinical visits.
Expansion of E-Commerce, DTC Models, And Fertility-Focused Healthcare Ecosystems
The rapid growth of e-commerce platforms and direct-to-consumer (DTC) healthcare models has significantly improved access to fertility testing devices worldwide. Online pharmacies, brand-owned websites, and subscription-based models enable discreet purchasing and repeat usage of consumables such as test strips and cartridges. Additionally, partnerships between fertility device manufacturers, telehealth providers, and fertility clinics are strengthening integrated care pathways from home testing to professional consultation thereby expanding market penetration and long-term customer engagement across developed and emerging markets.
Market Segmentation
- Based on the product type, the market is segmented into ovulation prediction kits, fertility monitors, and male fertility testing products.
- Based on the mode of purchase, the market is segmented into over‑the‑counter (OTC), and prescription‑based.
- Based on the end-user, the market is segmented into hospitals and fertility clinics, and home care setting.
Ovulation prediction kits (OPKs) represent the largest and leading segment in the Global Fertility Testing Devices Market, driven primarily by their widespread adoption in home care settings and strong availability through over-the-counter (OTC) channels. Within this category, urine-based ovulation kits dominate due to their high accuracy in detecting luteinizing hormone (LH) surges, affordability, ease of use, and rapid results, making them the preferred first-line fertility assessment tool for women trying to conceive. The growing awareness of reproductive health, increasing incidence of delayed pregnancies, and rising preference for non-invasive, self-administered fertility testing solutions have significantly boosted demand for OPKs compared to fertility monitors and male fertility testing products. Additionally, strong retail penetration, e-commerce growth, and minimal regulatory barriers for OTC products further reinforce the leadership of ovulation prediction kits, positioning this segment as the largest contributor to overall market revenue and growth globally.
Home Care Setting: A Key Segment in Market Growth
The home care setting represents the single most influential and fastest-growing segment in the global fertility testing devices market, driven by a strong shift toward self-managed and preventive reproductive health. Increasing awareness of fertility planning among women and couples, combined with delayed parenthood trends, has significantly boosted demand for convenient, private, and easy-to-use testing solutions that can be used at home. Home-based fertility testing devices such as ovulation prediction kits, hormone monitoring strips, and digital fertility trackers offer advantages including affordability, anonymity, and rapid results, making them highly attractive compared to clinic-based testing. The expansion of over-the-counter (OTC) availability further supports this segment, enabling consumers to purchase devices without medical consultations. Technological advancements, including smartphone connectivity, AI-based cycle tracking, and app-integrated hormone analysis, have improved accuracy and user engagement, strengthening consumer confidence in home testing.
Additionally, growing female workforce participation and busy lifestyles have increased the preference for at-home diagnostics that reduce time and cost burdens associated with hospital visits. In emerging economies, rising disposable income and expanding e-commerce platforms have improved access to home fertility testing products, accelerating adoption. Post-pandemic behavioral changes emphasizing remote and self-care diagnostics have also had a lasting positive impact. As a result, the home care setting is expected to remain the primary growth engine of the fertility testing devices market over the forecast period, outpacing hospital and clinic-based usage.
Regional Outlook
The global fertility testing devices market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global fertility testing devices market, accounting for the largest revenue share globally. This leadership is primarily driven by high awareness of fertility health, a strong culture of proactive reproductive planning, and widespread acceptance of at-home diagnostic testing. The US has a high prevalence of delayed parenthood, with many individuals choosing to conceive later in life due to career and lifestyle priorities, which significantly increases demand for ovulation prediction kits, digital fertility monitors, hormone-based tests, and at-home semen analysis devices. In addition, the country benefits from a well-established healthcare infrastructure, strong purchasing power, and extensive insurance and employer-supported fertility benefits that indirectly encourage fertility testing adoption.
The presence of leading fertility testing device manufacturers and brands such as Swiss Precision Diagnostics (Clearblue), Church & Dwight (First Response), Procter & Gamble, and several digital fertility startups further strengthens market dominance through continuous product innovation and aggressive direct-to-consumer marketing. Moreover, the rapid expansion of e-commerce, subscription-based testing models, and telehealth fertility platforms in the US has improved product accessibility and consumer engagement. Regulatory clarity for over-the-counter diagnostic devices and high penetration of digital health technologies also support faster commercialization and adoption of advanced fertility testing solutions, enabling the United States to maintain a commanding share of the global fertility testing devices market.
Market Players Outlook
The major companies operating in the global fertility testing devices market include Abbott Laboratories, Church & Dwight Co., Inc., Prestige Consumer Healthcare Inc., Swiss Precision Diagnostics (SPD) GmbH, Quidel Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
- In December 2025, INVO Fertility signed a definitive purchase agreement to acquire Family Beginnings, P.C., a fertility clinic in Indiana. This agreement follows INVO's announcement on November 27, 2025, and represents a step towards expanding its network of fertility care centers in the U.S. Family Beginnings reported revenues of approximately $1.2 million and a net income of about $0.2 million over the past year.
- In August 2023, Fertilly, launched Europe’s first At-Home Fertility Test Kits utilizing CE-IVD registered Mitra microsampling devices with VAMS technology. These medically certified kits allow individuals to collect dried blood samples at home via a quick finger-stick, which are then mailed to a lab for analysis. The Mitra devices ensure high-quality samples, minimizing the risk of inaccurate lab results. The test measures anti-Müllerian hormone (AMH) levels, indicating ovarian reserve, and provides women with personalized reports detailing their fertility status. Higher AMH levels correlate with better chances of natural conception or successful fertility treatments.
- In July 2023, Quest Diagnostics and Proov collaborated to offer the Proov Confirm PdG home fertility test kit through questhealth.com. It is the first FDA-cleared home test for measuring progesterone metabolite (PdG) to confirm ovulation. This test, aimed at women looking to start or expand their families, assesses hormone levels during the implantation window. Alongside this, Quest's offerings include a range of fertility assessment tests such as the Ovarian Reserve Assessment Marker Test, hCG Pregnancy Test, Pre-Pregnancy Test Panel, and Testosterone Test for men.
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global fertility testing devices market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Industry Overview
Fertility testing devices market was valued at $2.7 billion in 2025 and is projected to reach $5.6 billion by 2035, growing at a CAGR of 7.7% during the forecast Period (2026-2035). The market growth is driven by rising delayed pregnancies, increased infertility awareness, and tech advances like AI wearables and home sperm tests, making tracking easier. Key factors boosting growth include women delaying family for careers, rising PCOS cases, easy e-commerce access, and emerging male testing, though high costs and regulatory hurdles pose challenges. North America & Europe lead, but Asia-Pacific shows high growth owing to rising awareness.
Market Dynamics
Rising Infertility Prevalence and Delayed Parenthood
Globally, infertility rates are increasing due to lifestyle changes, stress, obesity, smoking, environmental exposure, and delayed family planning. Couples are choosing to conceive later in life, which heightens the need for early and regular fertility assessment. This demographic shift has made fertility testing devices such as ovulation prediction kits, hormone-based tests, and semen analysis tools an essential first step in reproductive planning. Growing awareness about fertility health among both women and men is encouraging proactive monitoring, significantly driving demand for easy-to-use, non-invasive, and affordable testing solutions.
Technological Advancements and Shift Toward Home-Based Diagnostics
Continuous innovation in fertility testing technologies is a major growth driver. The market is witnessing a transition from conventional strip-based tests to digital fertility monitors, smartphone-connected devices, and AI-enabled hormone tracking systems. These advanced devices offer higher accuracy, real-time data interpretation, and personalized insights, improving user confidence and outcomes. The convenience, privacy, and cost-effectiveness of home-based fertility testing devices are accelerating adoption, especially among tech-savvy consumers and those seeking alternatives to frequent clinical visits.
Expansion of E-Commerce, DTC Models, And Fertility-Focused Healthcare Ecosystems
The rapid growth of e-commerce platforms and direct-to-consumer (DTC) healthcare models has significantly improved access to fertility testing devices worldwide. Online pharmacies, brand-owned websites, and subscription-based models enable discreet purchasing and repeat usage of consumables such as test strips and cartridges. Additionally, partnerships between fertility device manufacturers, telehealth providers, and fertility clinics are strengthening integrated care pathways from home testing to professional consultation thereby expanding market penetration and long-term customer engagement across developed and emerging markets.
Market Segmentation
- Based on the product type, the market is segmented into ovulation prediction kits, fertility monitors, and male fertility testing products.
- Based on the mode of purchase, the market is segmented into over‑the‑counter (OTC), and prescription‑based.
- Based on the end-user, the market is segmented into hospitals and fertility clinics, and home care setting.
Ovulation prediction kits (OPKs) represent the largest and leading segment in the Global Fertility Testing Devices Market, driven primarily by their widespread adoption in home care settings and strong availability through over-the-counter (OTC) channels. Within this category, urine-based ovulation kits dominate due to their high accuracy in detecting luteinizing hormone (LH) surges, affordability, ease of use, and rapid results, making them the preferred first-line fertility assessment tool for women trying to conceive. The growing awareness of reproductive health, increasing incidence of delayed pregnancies, and rising preference for non-invasive, self-administered fertility testing solutions have significantly boosted demand for OPKs compared to fertility monitors and male fertility testing products. Additionally, strong retail penetration, e-commerce growth, and minimal regulatory barriers for OTC products further reinforce the leadership of ovulation prediction kits, positioning this segment as the largest contributor to overall market revenue and growth globally.
Home Care Setting: A Key Segment in Market Growth
The home care setting represents the single most influential and fastest-growing segment in the global fertility testing devices market, driven by a strong shift toward self-managed and preventive reproductive health. Increasing awareness of fertility planning among women and couples, combined with delayed parenthood trends, has significantly boosted demand for convenient, private, and easy-to-use testing solutions that can be used at home. Home-based fertility testing devices such as ovulation prediction kits, hormone monitoring strips, and digital fertility trackers offer advantages including affordability, anonymity, and rapid results, making them highly attractive compared to clinic-based testing. The expansion of over the counter (OTC) availability further supports this segment, enabling consumers to purchase devices without medical consultations. Technological advancements, including smartphone connectivity, AI-based cycle tracking, and app-integrated hormone analysis, have improved accuracy and user engagement, strengthening consumer confidence in home testing.
Additionally, growing female workforce participation and busy lifestyles have increased the preference for at-home diagnostics that reduce time and cost burdens associated with hospital visits. In emerging economies, rising disposable income and expanding e-commerce platforms have improved access to home fertility testing products, accelerating adoption. Post-pandemic behavioral changes emphasizing remote and self-care diagnostics have also had a lasting positive impact. As a result, the home care setting is expected to remain the primary growth engine of the fertility testing devices market over the forecast period, outpacing hospital and clinic-based usage.
Regional Outlook
The global fertility testing devices market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global fertility testing devices market, accounting for the largest revenue share globally. This leadership is primarily driven by high awareness of fertility health, a strong culture of proactive reproductive planning, and widespread acceptance of at-home diagnostic testing. The US has a high prevalence of delayed parenthood, with many individuals choosing to conceive later in life due to career and lifestyle priorities, which significantly increases demand for ovulation prediction kits, digital fertility monitors, hormone-based tests, and at-home semen analysis devices. In addition, the country benefits from a well-established healthcare infrastructure, strong purchasing power, and extensive insurance and employer-supported fertility benefits that indirectly encourage fertility testing adoption.
The presence of leading fertility testing device manufacturers and brands such as Swiss Precision Diagnostics (Clearblue), Church & Dwight (First Response), Procter & Gamble, and several digital fertility startups further strengthens market dominance through continuous product innovation and aggressive direct-to-consumer marketing. Moreover, the rapid expansion of e-commerce, subscription-based testing models, and telehealth fertility platforms in the US has improved product accessibility and consumer engagement. Regulatory clarity for over-the-counter diagnostic devices and high penetration of digital health technologies also support faster commercialization and adoption of advanced fertility testing solutions, enabling the United States to maintain a commanding share of the global fertility testing devices market.
Market Players Outlook
The major companies operating in the global fertility testing devices market include Abbott Laboratories, Church & Dwight Co., Inc., Prestige Consumer Healthcare Inc., Swiss Precision Diagnostics (SPD) GmbH, Quidel Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
- In December 2025, INVO Fertility signed a definitive purchase agreement to acquire Family Beginnings, P.C., a fertility clinic in Indiana. This agreement follows INVO's announcement on November 27, 2025, and represents a step towards expanding its network of fertility care centers in the U.S. Family Beginnings reported revenues of approximately $1.2 million and a net income of about $0.2 million over the past year.
- In August 2023, Fertilly, launched Europe’s first At-Home Fertility Test Kits utilizing CE-IVD registered Mitra microsampling devices with VAMS technology. These medically certified kits allow individuals to collect dried blood samples at home via a quick finger-stick, which are then mailed to a lab for analysis. The Mitra devices ensure high-quality samples, minimizing the risk of inaccurate lab results. The test measures anti-Müllerian hormone (AMH) levels, indicating ovarian reserve, and provides women with personalized reports detailing their fertility status. Higher AMH levels correlate with better chances of natural conception or successful fertility treatments.
- In July 2023, Quest Diagnostics and Proov collaborated to offer the Proov Confirm PdG home fertility test kit through questhealth.com. It is the first FDA-cleared home test for measuring progesterone metabolite (PdG) to confirm ovulation. This test, aimed at women looking to start or expand their families, assesses hormone levels during the implantation window. Alongside this, Quest's offerings include a range of fertility assessment tests such as the Ovarian Reserve Assessment Marker Test, hCG Pregnancy Test, Pre-Pregnancy Test Panel, and Testosterone Test for men.
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global fertility testing devices market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
189 Pages
- 1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Fertility Testing Devices Market Sales Analysis – Product Type Mode of Purchase End-User ($ Million)
- Fertility Testing Devices Market Sales Performance of Top Countries
- 1.1. Research Methodology
- Primary Research Approach
- Secondary Research Approach
- 1.2. Market Snapshot
- 2. Market Overview and Insights
- 2.1. Scope of the Study
- 2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Fertility Testing Devices Market Trends
- 2.2.2. Market Recommendations
- 2.3. Porter's Five Forces Analysis for the Fertility Testing Devices Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes
- 3. Market Determinants
- 3.1. Market Drivers
- 3.1.1. Drivers For Global Fertility Testing Devices Market: Impact Analysis
- 3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Fertility Testing Devices Market: Impact Analysis
- 3.3. Market Opportunities
- 3.3.1. Opportunities For Global Fertility Testing Devices Market: Impact Analysis
- 4. Competitive Landscape
- 4.1. Competitive Dashboard – Fertility Testing Devices Market Revenue and Share by Manufacturers
- Fertility Testing Devices Mode of Purchase Comparison Analysis
- Top Market Player Ranking Matrix
- 4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
- 4.2.1.1. Overview
- 4.2.1.2. Mode of Purchase Portfolio
- 4.2.1.3. Financial Analysis
- 4.2.1.4. SWOT Analysis
- 4.2.1.5. Business Strategy
- 4.2.2. Church & Dwight Co., Inc.
- 4.2.2.1. Overview
- 4.2.2.2. Mode of Purchase Portfolio
- 4.2.2.3. Financial Analysis
- 4.2.2.4. SWOT Analysis
- 4.2.2.5. Business Strategy
- 4.2.3. Prestige Consumer Healthcare Inc.
- 4.2.3.1. Overview
- 4.2.3.2. Mode of Purchase Portfolio
- 4.2.3.3. Financial Analysis
- 4.2.3.4. SWOT Analysis
- 4.2.3.5. Business Strategy
- 4.2.4. Swiss Precision Diagnostics (SPD) GmbH
- 4.2.4.1. Overview
- 4.2.4.2. Mode of Purchase Portfolio
- 4.2.4.3. Financial Analysis
- 4.2.4.4. SWOT Analysis
- 4.2.4.5. Business Strategy
- 4.2.5. Quidel Corp.
- 4.2.5.1. Overview
- 4.2.5.2. Mode of Purchase Portfolio
- 4.2.5.3. Financial Analysis
- 4.2.5.4. SWOT Analysis
- 4.2.5.5. Business Strategy
- 4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Mode of Purchase Launch
- 4.3.3. Partnership And Collaboration
- 5. Global Fertility Testing Devices Market Sales Analysis by Product Type ($ Million)
- 5.1. Ovulation Prediction Kits
- 5.2. Fertility Monitors
- 5.2.1. Urine-based Ovulation Kits
- 5.2.2. Saliva-based Ovulation Kits
- 5.2.3. Other Fertility Monitors
- 5.3. Male Fertility Testing Mode of Purchases
- 6. Global Fertility Testing Devices Market Sales Analysis by Mode of Purchase ($ Million)
- 6.1. Over‑the‑Counter (OTC)
- 6.2. Prescription‑Based
- 7. Global Fertility Testing Devices Market Sales Analysis by End-User ($ Million)
- 7.1. Hospitals and Fertility Clinics
- 7.2. Home Care Setting
- 8. Regional Analysis
- 8.1. North American Fertility Testing Devices Market Sales Analysis – Product Type Mode of Purchase End-User Country ($ Million)
- Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
- 8.2. European Fertility Testing Devices Market Sales Analysis – Product Type Mode of Purchase End-User Country ($ Million)
- Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
- 8.3. Asia-Pacific Fertility Testing Devices Market Sales Analysis – Product Type Mode of Purchase End-User Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
- 8.4. Rest of the World Fertility Testing Devices Market Sales Analysis – Product Type Mode of Purchase End-User Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa
- 9. Company Profiles
- 9.1. Abbott Laboratories, Inc.
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
- 9.2. AdvaCare Pharma
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
- 9.3. Alere Inc.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
- 9.4. Ava Science Inc.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
- 9.5. Babystart Ltd.
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
- 9.6. bioZhena Corp.
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
- 9.7. Church & Dwight Co., Inc.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
- 9.8. Clearblue (brand of Swiss Precision Diagnostics GmbH)
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
- 9.9. Fairhaven Health, LLC
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
- 9.10. Fertility Focus Ltd.
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
- 9.11. Geratherm Medical AG
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
- 9.12. HiLin Life Products Inc.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
- 9.13. Labcorp
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
- 9.14. Prestige Consumer Healthcare Inc.
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
- 9.15. Procter & Gamble
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
- 9.16. Quidel Corp.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
- 9.17. Roche Diagnostics
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
- 9.18. Swiss Precision Diagnostics GmbH (SPD)
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
- 9.19. Thermo Fisher Scientific, Inc.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
- 9.20. Valley Electronics AG
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
